ABUS · Arbutus Biopharma Corp
United States · RS rating 22 · As of 2026-10-14
| Price | 4.19 USD |
|---|---|
| 1-day change | +1.9% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 14 / 29 / 41 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 35 / 27 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -103.5% |
| Sales growth Q/Q | +98.7% |
| Distance from 52-week high | +19.7% |
| Market cap (USD) | $837.0M |